Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAP Regimen for HSC Mobilization in Lymphoma and Multiple Myeloma
NCT05536154Recruiting
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of etoposide, cytarabine and pegfilgrastim in lymphoma and multiple myeloma (MM), sponsored by The Affiliated People’s Hospital of Ningbo University. Primary endpoint: Percentage of patients achieving the collection of >=2x10^6 CD34+ cells/kg at 4 weeks. Started Nov 2022; status: recruiting.
02
Drugs
etoposidecytarabinepegfilgrastim
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05536154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536154.